Related content

Levodopa-Induced Response Fluctuations in Patients with Parkinson’s Disease: Strategies for Management

By van Laar T.  

CNS Drugs, Vol. 17, Iss. 7, 2003-01 ,pp. : 475-489

Adis International

Access to resources Recommend Favorite

Receptor Heteromers in Parkinson’s Disease and L-DOPA-Induced Dyskinesia

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 12, Iss. 8, 2013-12 ,pp. : 1101-1113

Bentham Science Publishers

Access to resources Recommend Favorite

Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System

By  

Current Medicinal Chemistry, Vol. 23, Iss. 9, 2016-03 ,pp. : 874-883

Bentham Science Publishers

Access to resources Recommend Favorite

Animal models of Parkinson’s disease and L-dopa induced dyskinesia: How close are we to the clinic?

By Lane Emma   Dunnett Stephen  

Psychopharmacology, Vol. 199, Iss. 3, 2008-08 ,pp. : 303-312

Springer Publishing Company

Access to resources Recommend Favorite

Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson’s disease in the MPTP-induced mice model

By Xiang Yu   Wu Qian   Liang Liang   Wang Xueqing   Wang Jiancheng   Zhang Xuan   Pu Xiaoping   Zhang Qiang  

Journal of Drug Targeting, Vol. 20, Iss. 1, 2012-01 ,pp. : 67-75

Informa Healthcare

Access to resources Recommend Favorite